Global Cell and Gene Therapy CDMO Market Insights, Size, and Forecast By Application Indication (Oncology, Immunology, Neurology, Cardiovascular, Other Diseases), By Product (Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Cell and Gene Therapy CDMO Market is projected to grow from USD 14.2 Billion in 2025 to USD 48.2 Billion by 2035, reflecting a compound annual growth rate of 17.4% from 2026 through 2035.
Global Cell and Gene Therapy CDMO Market Market Value (USD Billion) Analysis, 2025-2035
The cell and gene therapy Contract Development and Manufacturing Organization (CDMO) market encompasses the outsourcing of various services related to the development and manufacturing of cell and gene therapies. This includes process development, analytical testing, regulatory support, and clinical and commercial manufacturing for viral vectors, plasmids, cell banks, and cell products. The market's robust expansion is primarily driven by the burgeoning pipeline of cell and gene therapies, increasing R&D investments by biopharmaceutical companies, and the inherent complexities and high costs associated with in-house manufacturing. Many therapy developers, particularly smaller biotech firms, lack the specialized expertise, infrastructure, and capital required for compliant and efficient production, making CDMOs indispensable partners. Furthermore, the rapid advancements in gene editing technologies and a growing understanding of disease mechanisms are fueling the development of innovative therapeutic candidates, consequently boosting demand for CDMO services.
However, the market also faces certain restraints, including the significant regulatory hurdles and the need for stringent quality control measures throughout the manufacturing process. The scarcity of skilled labor with expertise in advanced therapeutic medicinal products (ATMPs) and the substantial capital investment required for establishing and maintaining state-of-the-art facilities also pose challenges. Despite these hurdles, significant opportunities exist within the expanding range of therapeutic applications beyond oncology, such as rare diseases, neurological disorders, and cardiovascular conditions. The increasing adoption of advanced manufacturing technologies like automation and continuous manufacturing, coupled with the strategic expansion of CDMOs into new geographies, presents avenues for further growth. North America currently dominates the market, attributable to a mature biotechnology industry, a high concentration of pharmaceutical and biotech companies, substantial R&D funding, and a favorable regulatory environment for advanced therapies. The region benefits from early adoption and robust innovation in gene therapy. Conversely, Asia Pacific is poised to be the fastest-growing region, driven by rising healthcare expenditures, a large patient pool, increasing government support for biotechnology, and growing outsourcing trends as Western companies look to leverage cost-effective manufacturing capabilities and access new markets.
Key players in this competitive landscape, such as Thermo Fisher Scientific, Emergent BioSolutions, Curia, Lonza, Recipharm, Syngene, Genscript, Eurofins, Wacker, and Charles River Laboratories, are actively pursuing strategies to solidify their market positions. These strategies typically involve expanding manufacturing capacities, investing in advanced technologies, forging strategic alliances and partnerships, and acquiring smaller CDMOs to broaden their service offerings and geographical reach. For instance, many are focusing on end-to-end solutions, from early-stage process development to commercial-scale manufacturing, to become a single point of contact for their clients. The leading segment by application indication is Oncology, reflecting the extensive research and development efforts, coupled with significant clinical successes, in developing cell and gene therapies for various cancers. This segment benefits from a high unmet medical need and strong investment interest, driving continuous innovation and demand for specialized manufacturing services from CDMOs.
Quick Stats
Market Size (2025):
USD 14.2 BillionProjected Market Size (2035):
USD 48.2 BillionLeading Segment:
Oncology (74.8% Share)Dominant Region (2025):
North America (48.5% Share)CAGR (2026-2035):
17.4%
Global Cell and Gene Therapy CDMO Market Emerging Trends and Insights
AI-Driven Process Optimization and Predictive Analytics in CGT CDMOs
North American CGT CDMOs are increasingly adopting AI to transform manufacturing and logistics. This trend leverages AI's power to analyze vast datasets from production runs, quality control, and supply chains. AI-driven process optimization identifies inefficiencies, predicts equipment failures, and fine-tunes parameters to maximize yield and reduce costs for complex cell and gene therapies. Predictive analytics anticipate potential bottlenecks, raw material shortages, or deviations in product quality, enabling proactive interventions. This shift moves away from reactive problem-solving towards a data-driven, predictive model, enhancing manufacturing reliability, accelerating time-to-market, and ensuring consistent product quality, ultimately delivering therapies to patients faster and more efficiently.
Decentralized Manufacturing and Point-of-Care CDMO Models for CGT
The CGT CDMO market is seeing a shift towards decentralized manufacturing, moving production closer to patient care. This trend involves establishing smaller, regionally distributed manufacturing facilities, contrasting with traditional large, centralized sites.
Simultaneously, "Point-of-Care (POC) CDMO models" are emerging. These models integrate manufacturing directly within or very near clinical settings, sometimes even within hospitals. This significantly reduces logistical complexities and transport times for highly sensitive, time-critical CGT products. Both trends aim to improve supply chain efficiency, reduce product degradation risks, and ensure faster delivery of personalized therapies. This also supports scalability and accessibility, particularly important given the personalized nature of many CGT products and the dominance of North America in their development and commercialization.
Enhanced Viral Vector Manufacturing Platforms and Capacity Expansion
The enhanced viral vector manufacturing trend signifies a critical advancement in the Global Cell and Gene Therapy CDMO Market. As gene therapies become more prevalent, the demand for high-quality, scalable viral vectors – crucial delivery vehicles for genetic material – has surged. CDMOs are responding by investing in platforms that offer improved yields, reduced manufacturing times, and enhanced safety profiles for AAV, lentiviral, and other vector types. This involves adopting closed systems, single-use technologies, and advanced analytics for better process control and characterization. Concurrently, capacity expansion, particularly in North America, addresses the bottleneck in vector supply, enabling quicker progression from clinical trials to commercialization. This dual focus ensures that the infrastructure exists to meet the increasing and complex manufacturing needs of a rapidly evolving therapeutic landscape.
What are the Key Drivers Shaping the Global Cell and Gene Therapy CDMO Market
Surging Biopharmaceutical R&D and Clinical Pipeline Expansion
The robust expansion of biopharmaceutical research and development, particularly within the cell and gene therapy (CGT) sector, is a primary growth driver for the global CGT CDMO market. As companies worldwide intensify their efforts to discover and develop novel gene-edited cells, viral vectors, and advanced cellular immunotherapies, the demand for specialized manufacturing expertise and infrastructure skyrockets. This surge in R&D translates into a rapidly growing clinical pipeline, with more CGT candidates progressing through preclinical and clinical trial phases. Biopharmaceutical firms, often lacking the in-house capabilities for complex and costly CGT manufacturing, increasingly rely on Contract Development and Manufacturing Organizations (CDMOs) to navigate intricate regulatory requirements, ensure quality control, and scale production efficiently, thereby accelerating therapeutic development and market entry.
Advancements in Cell and Gene Therapy Modalities and Technologies
Advancements in cell and gene therapy (CGT) modalities and technologies are a pivotal driver for the Global Cell and Gene Therapy CDMO Market. As researchers uncover new therapeutic targets and refine delivery vectors, the complexity and diversity of CGT products are escalating. This includes the development of novel gene editing tools like CRISPR, induced pluripotent stem cell (iPSC) technologies, and sophisticated viral/non-viral gene delivery systems. Each new breakthrough in these areas often brings unique manufacturing challenges related to scalability, quality control, and regulatory compliance. Consequently, biopharmaceutical companies increasingly rely on Contract Development and Manufacturing Organizations (CDMOs) with specialized expertise and advanced infrastructure to navigate these complexities, accelerating the translation of innovative therapies from lab to clinic and fueling market growth.
Strategic Outsourcing by Biopharma to Accelerate Commercialization
Biopharma companies, particularly those developing cell and gene therapies, are increasingly leveraging strategic outsourcing to specialized Contract Development and Manufacturing Organizations (CDMOs). This driver stems from the need to expedite the complex journey from clinical trials to market commercialization. Cell and gene therapies demand highly specialized expertise in areas like viral vector manufacturing, cell processing, and aseptic fill-finish, often beyond the in-house capabilities of many biopharma innovators. By partnering with experienced CDMOs, biopharma firms can access cutting-edge technologies, scale manufacturing efficiently, navigate stringent regulatory pathways, and mitigate risks associated with facility build-out and talent acquisition. This allows them to focus internal resources on R&D, accelerating patient access to groundbreaking treatments.
Global Cell and Gene Therapy CDMO Market Restraints
Stringent Regulatory Landscape for ATMPs
The stringent regulatory landscape for Advanced Therapy Medicinal Products (ATMPs) significantly constrains the Global Cell and Gene Therapy CDMO Market. Developing and manufacturing ATMPs involves navigating complex and evolving regulations across different jurisdictions (e.g., FDA, EMA). This encompasses rigorous requirements for product quality, safety, efficacy, manufacturing processes (GMP), and clinical trial protocols. Each stage, from raw material sourcing and cell banking to aseptic filling and final product release, is subject to intense scrutiny. Meeting these diverse and often country-specific requirements necessitates substantial investment in specialized facilities, highly trained personnel, robust quality management systems, and extensive documentation. This elevated cost and prolonged development timelines due to regulatory hurdles deter new entrants and present a significant barrier to market expansion for CDMOs, as compliance demands specialized expertise and significant resource allocation.
High Capital Investment and Specialized Infrastructure Requirements
Operating in the Global Cell and Gene Therapy CDMO market necessitates substantial upfront financial commitments. Establishing and maintaining the sophisticated facilities required for compliant cell and gene therapy manufacturing involves significant capital expenditure. This includes constructing specialized cleanrooms, acquiring advanced bioprocessing equipment, and implementing robust quality control laboratories. Furthermore, the highly specialized nature of these therapies demands dedicated infrastructure tailored to specific cell types, viral vectors, or gene editing technologies. This includes specialized cold chain storage, aseptic processing capabilities, and highly controlled environments to prevent contamination and ensure product integrity. These extensive infrastructure requirements and the associated high investment act as a significant barrier to entry and expansion for many potential CDMOs, limiting competition and creating a formidable restraint on market growth.
Global Cell and Gene Therapy CDMO Market Opportunities
Pioneering Scalable Manufacturing Platforms for Allogeneic 'Off-the-Shelf' Therapies
The transition from patient-specific (autologous) to universal “off-the-shelf” (allogeneic) therapies represents a monumental opportunity for CDMOs. Allogeneic treatments, derived from a single healthy donor source, can be manufactured in large batches to treat many patients, fundamentally changing the economics and accessibility of cell therapy.
However, this model demands a paradigm shift in manufacturing. The key opportunity lies in developing and validating novel, scalable platforms that can consistently produce vast quantities of high-quality cells. This includes pioneering advanced bioreactor technologies, implementing closed-system automation to ensure sterility and consistency, and integrating sophisticated analytical tools for quality control.
CDMOs that successfully build these robust, industrial-scale platforms will become indispensable partners, capturing significant market share by enabling the commercial viability of next-generation therapies for a global patient population. They will effectively create the "factory model" for the future of regenerative medicine.
Expanding into End-to-End Service Models: Integrating Plasmid, Vector, and Cell Processing Capabilities
A significant opportunity lies in transitioning from specialized services to a fully integrated, end-to-end model. Currently, therapy developers often navigate a fragmented supply chain, contracting separate CDMOs for plasmid DNA manufacturing, viral or non-viral vector production, and final cell processing. This creates logistical hurdles, increases timelines, and introduces risks at each handoff.
By consolidating these critical capabilities under one roof, a CDMO can become a single-source strategic partner. This integrated approach offers immense value by simplifying supply chain management, accelerating development timelines from preclinical to commercial stages, and ensuring greater process control and quality consistency. For clients, it de-risks the complex manufacturing journey. For the CDMO, it creates a powerful competitive advantage, fostering deeper client relationships and capturing a greater share of the value chain. This model directly addresses the market’s need for speed and efficiency in bringing novel therapies to patients.
Global Cell and Gene Therapy CDMO Market Segmentation Analysis
Key Market Segments
By Product
- •Cell Therapy
- •Gene Therapy
- •Gene-Modified Cell Therapy
By Application Indication
- •Oncology
- •Immunology
- •Neurology
- •Cardiovascular
- •Other Diseases
Why does the oncology segment overwhelmingly dominate the Global Cell and Gene Therapy CDMO market?
The segment's dominance is driven by the high prevalence of cancer and substantial R&D investment, leading to a robust pipeline of cancer-focused therapies. Groundbreaking treatments, particularly gene-modified cell therapies like CAR-T, have seen significant clinical success and regulatory approvals. This success fuels a continuous demand for specialized manufacturing capacity, making oncology the primary revenue driver for CDMOs who provide the intricate viral vector production and cell processing services required for these advanced treatments.
How do the cell, gene, and gene-modified cell therapy product segments distinctly shape CDMO service demand?
Each product segment requires unique manufacturing expertise. Cell therapy focuses on the complex logistics of culturing and processing patient or donor cells. Gene therapy centers on producing viral vectors to deliver genetic payloads. Gene-modified cell therapy represents the most complex demand, merging both disciplines by requiring sophisticated vector manufacturing and ex-vivo cell engineering. This multifaceted process drives strong reliance on specialized CDMOs capable of handling the entire integrated workflow from start to finish.
Beyond oncology, which application indications are creating new growth avenues for cell and gene therapy CDMOs?
While oncology leads, immunology, neurology, and cardiovascular diseases represent significant emerging frontiers. Increasing research into treatments for autoimmune disorders, neurodegenerative conditions, and inherited heart diseases is expanding the therapeutic pipeline. These areas, along with a focus on rare genetic disorders, are diversifying the market. As these novel therapies advance through clinical trials, they create new, specialized manufacturing demands for CDMOs to support different cell types and delivery vectors.
Global Cell and Gene Therapy CDMO Market Regulatory and Policy Environment Analysis
The global cell and gene therapy CDMO market operates within a complex and evolving regulatory landscape characterized by regional fragmentation. While agencies like the U.S. FDA and the EMA are establishing clearer frameworks, a lack of global harmonization creates significant compliance challenges for CDMOs. Stringent Good Manufacturing Practices (GMP) and robust Chemistry, Manufacturing, and Controls (CMC) documentation remain paramount, with intense scrutiny on process validation, raw material sourcing, and data integrity.
Supportive government policies, including accelerated approval pathways like RMAT and PRIME, stimulate market growth by encouraging therapeutic development. However, these programs also demand sophisticated manufacturing capabilities and regulatory expertise from CDMO partners. The push for greater standardization through bodies like the ICH and public-private partnerships aims to streamline development. Navigating these dynamic requirements is critical for CDMOs, positioning regulatory proficiency as a key competitive differentiator in the market.
Which Emerging Technologies Are Driving New Trends in the Market?
The Cell and Gene Therapy CDMO market is propelled by a wave of technological innovation. Automation and robotics are central, enabling closed, end-to-end manufacturing systems that enhance scalability, reduce contamination risks, and ensure consistency. Artificial intelligence and machine learning are increasingly integrated for predictive analytics, optimizing bioreactor conditions and streamlining complex supply chains. Innovations in vector manufacturing, particularly in AAV and lentiviral platforms alongside emerging non-viral delivery methods, are expanding therapeutic reach. Advanced analytical technologies, including next-generation sequencing and multi-omic profiling, provide deeper process understanding and more robust quality control. Furthermore, the adoption of modular facilities and single-use technologies offers greater flexibility and speed. These advancements are critical for CDMOs to manage the complexity and scale required for both autologous and allogeneic therapies, ultimately accelerating the delivery of life-changing treatments to patients worldwide and fostering market expansion through enhanced capabilities.
Global Cell and Gene Therapy CDMO Market Regional Analysis
Global Cell and Gene Therapy CDMO Market Regional Analysis in 2025
North America is Expected to Hold the Largest Global Cell and Gene Therapy CDMO Market Market Share
Dominant Region
North America · 48.5% share
North America unequivocally dominates the global cell and gene therapy CDMO market, securing a substantial 48.5% market share. This translates to an estimated market size of USD 14.2 billion, highlighting the region's immense contribution and leadership. Several factors fuel this dominance, including a robust ecosystem of pharmaceutical and biotechnology companies, extensive R&D investments, and a well-established regulatory framework that fosters innovation and commercialization. The presence of numerous academic research institutions and a strong venture capital landscape further accelerate the development and outsourcing of cell and gene therapies. This confluence of factors positions North America as the critical hub for advanced therapeutic manufacturing and development.
Fastest Growing Region
Asia Pacific · 28.2% CAGR
The Asia Pacific region is poised to be the fastest-growing market in the global Cell and Gene Therapy CDMO sector, exhibiting an impressive CAGR of 28.2% during the forecast period of 2026-2035. This accelerated growth is primarily driven by several key factors. Increasing investments in biopharmaceutical R&D across countries like China, India, and South Korea are fueling demand for specialized CDMO services. Furthermore, a rising prevalence of chronic and genetic diseases, coupled with growing awareness and acceptance of advanced therapies, is creating a robust market. The presence of a large patient pool, expanding healthcare infrastructure, and supportive government initiatives promoting biotechnology and pharmaceutical innovation further solidify Asia Pacific's leading growth trajectory.
Impact of Geopolitical and Macroeconomic Factors
The cell and gene therapy (CGT) CDMO market, though robust, faces geopolitical headwinds. Increasing nationalistic policies and onshoring initiatives, particularly within North America and Europe, could fragment supply chains and necessitate localized manufacturing investments, potentially slowing global expansion. Regulatory divergence, with differing approval processes and manufacturing standards across major economies like the US, EU, and China, further complicates global CDMO operations and market access, increasing compliance costs and operational complexities for multi-national players.
Macroeconomically, sustained high inflation and interest rates could pressure CDMO profitability by increasing operational costs, including raw materials, specialized labor, and facility expansion. Conversely, robust venture capital funding and continued government support for life sciences, particularly in North America, provide a strong tailwind, attracting investment and driving demand for specialized CGT manufacturing services. However, a global economic slowdown or recession could temper biopharma R&D spending, impacting the pipeline of therapies progressing to clinical and commercial stages, thereby moderating CDMO growth.
Recent Developments
- March 2025
Lonza announced a strategic partnership with a leading biotech firm to develop and manufacture novel allogeneic CAR-T cell therapies. This collaboration aims to leverage Lonza's advanced manufacturing capabilities and the biotech's innovative therapeutic pipeline to accelerate market access for these complex therapies.
- January 2025
Thermo Fisher Scientific completed the acquisition of a specialized gene therapy manufacturing facility in Europe, significantly expanding its global footprint. This acquisition enhances Thermo Fisher's capacity for viral vector production and reinforces its position as a key player in the European cell and gene therapy CDMO market.
- November 2024
Curia launched a new state-of-the-art plasmid DNA manufacturing suite, offering enhanced capacity and advanced analytical capabilities for gene therapy clients. This expansion addresses the growing demand for high-quality, clinical-grade plasmid DNA, a critical raw material for many gene therapy applications.
- September 2024
Charles River Laboratories announced a joint venture with a burgeoning Asian biotech company to establish a dedicated cell therapy manufacturing center in Singapore. This strategic initiative aims to tap into the rapidly growing Asian market for cell and gene therapies and provide localized support for regional clients.
Key Players Analysis
The global Cell and Gene Therapy CDMO market is characterized by a mix of established life science giants and specialized contract manufacturers, all vying for market share driven by the rapid pipeline expansion in advanced therapies. Thermo Fisher Scientific, a dominant player, leverages its vast ecosystem encompassing analytical instruments, reagents, and now CDMO services (through acquisitions like Brammer Bio) to offer integrated solutions from early development to commercial manufacturing. Their strength lies in end-to-end capabilities, a broad technology portfolio (viral vector manufacturing, cell processing), and significant investment in scale and automation. Lonza, another powerhouse, boasts deep expertise in biologics manufacturing and has strategically expanded its capabilities into cell and gene therapies with dedicated facilities and advanced platforms for viral vectors and cell therapies. Their focus on quality, regulatory compliance, and capacity expansion positions them as a preferred partner for complex projects.
Emergent BioSolutions, while historically strong in vaccines and therapeutics, is expanding its CDMO footprint into gene therapies, offering manufacturing capacity and process development expertise. Curia (formerly AMRI) and Recipharm are actively growing their presence, often through acquisitions, to offer more comprehensive services across the drug development lifecycle, including specialized capabilities for advanced therapies. Companies like Syngene, Genscript, and Eurofins contribute significantly with their strong research, development, and analytical testing services, often supporting early-stage process development and quality control for cell and gene therapy developers. Wacker and Charles River Laboratories are also making inroads, leveraging their existing biologics and preclinical expertise, respectively, to offer integrated solutions to the burgeoning cell and gene therapy sector. Strategic initiatives across these players include capacity expansion, technological innovation (e.g., AAV vector optimization, allogeneic cell therapy manufacturing), and forming strategic alliances to capture the growing demand driven by increasing approvals and pipeline maturity.
List of Key Companies:
- Thermo Fisher Scientific
- Emergent BioSolutions
- Curia
- Lonza
- Recipharm
- Syngene
- Genscript
- Eurofins
- Wacker
- Charles River Lobaoraties
- Pfizer CentreOne
- FUJIFILM Diosynth Biotechnologies
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 14.2 Billion |
| Forecast Value (2035) | USD 48.2 Billion |
| CAGR (2026-2035) | 17.4% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
Figure 1: Global Cell and Gene Therapy CDMO Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2035
Figure 2: Global Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025 & 2035
Figure 3: Global Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025 & 2035
Figure 4: Global Cell and Gene Therapy CDMO Market Value Share (%), by Region, 2025 & 2035
Figure 5: North America Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 6: North America Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 7: North America Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 8: North America Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 9: North America Cell and Gene Therapy CDMO Market Value (USD billion), by Country, 2025 & 2035
Figure 10: North America Cell and Gene Therapy CDMO Market Value Share (%), by Country, 2024
Figure 11: Europe Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 12: Europe Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 13: Europe Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 14: Europe Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 15: Europe Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 16: Europe Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 17: Asia Pacific Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 18: Asia Pacific Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 19: Asia Pacific Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 20: Asia Pacific Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 21: Asia Pacific Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 22: Asia Pacific Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 23: Latin America Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 24: Latin America Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 25: Latin America Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 26: Latin America Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 27: Latin America Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 28: Latin America Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 29: Middle East & Africa Cell and Gene Therapy CDMO Market Value (USD billion), by Product, 2025 & 2035
Figure 30: Middle East & Africa Cell and Gene Therapy CDMO Market Value Share (%), by Product, 2025
Figure 31: Middle East & Africa Cell and Gene Therapy CDMO Market Value (USD billion), by Application Indication, 2025 & 2035
Figure 32: Middle East & Africa Cell and Gene Therapy CDMO Market Value Share (%), by Application Indication, 2025
Figure 33: Middle East & Africa Cell and Gene Therapy CDMO Market Value (USD billion), by Country/ Sub-region, 2025 & 2035
Figure 34: Middle East & Africa Cell and Gene Therapy CDMO Market Value Share (%), by Country/ Sub-region, 2025
Figure 35: Global Cell and Gene Therapy CDMO Market Share (%), by Company, 2025
List of Tables
Table 1: Global Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 2: Global Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 3: Global Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 4: North America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 5: North America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 6: North America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 7: Europe Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 8: Europe Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 9: Europe Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 10: Asia Pacific Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 11: Asia Pacific Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 12: Asia Pacific Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 13: Latin America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 14: Latin America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 15: Latin America Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Middle East & Africa Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Product, 2020-2035
Table 17: Middle East & Africa Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Application Indication, 2020-2035
Table 18: Middle East & Africa Cell and Gene Therapy CDMO Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035